Bitcoin hits record high over $124k on rate cut bets, corporate treasury cheer
Investing.com -- ProPhase Labs Inc (NASDAQ:PRPH) stock surged 38% after the company announced it has secured a key patent for its biomarker-based system that assesses progression risk in Barrett’s esophagus and esophageal adenocarcinoma.
The United States Patent and Trademark Office issued U.S. Patent No. 12379378-B2 for the company’s methods that underpin its BE-Smart™ molecular diagnostic test. This patent protection follows ProPhase’s recent announcement that its BE-Smart™ test achieved greater than a 95% technical success rate in detecting the company’s panel of biomarkers.
The newly patented technology works with both esophageal brush cytology and forceps biopsies, which the company says enhances early detection capabilities. Brush biopsies capture broader epithelial cell populations while forceps biopsies provide targeted tissue sampling, potentially improving risk stratification in patients with various esophageal disorders.
"This achievement, coming on the heels of our BE-Smart™ validation demonstrating greater than a 95% technical success rate and dual compatibility with both brush and forceps biopsies, solidifies our leadership in medical innovation and brings us one step closer to transforming early detection and treatment strategies for this serious condition," said Ted Karkus, Chief Executive Officer of ProPhase Labs.
The patent, originally filed in December 2023, covers systems for assessing risk by detecting key biomarkers including ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. According to the company, these patented methods may also enable novel treatment approaches, including inhibiting cancer cell proliferation and enhancing tumor susceptibility to cytotoxic therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.